Emtricitabine rilpivirine tenofovir: Difference between revisions
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Emtricitabine/rilpivirine/tenofovir''' (trade name '''Complera''', '''Eviplera''') is a [[fixed-dose combination (antiretroviral)|fixed dose combination]] of [[antiretroviral]] drugs for the treatment of [[HIV]].<ref>{{cite web |title=Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination |url=http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm267592.htm |publisher=[[Food and Drug Administration]] |date=August 10, 2011 }}</ref> The drug was co-developed by [[Gilead Sciences]] and [[Johnson & Johnson]]'s [[Tibotec]] division and was approved by the [[Food and Drug Administration]] in August 2011, and by the [[European Medicines Agency]] in November 2011 (Eviplera),<ref>{{cite web |url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002312/human_med_001514.jsp&mid=WC0b01ac058001d124 |title=Eviplera; summary of the European public assessment report |publisher=[[European Medicines Agency]] |date=November 2011 }}</ref> for patients who have not previously been treated for HIV.<ref>{{cite web |url=http://www.businessweek.com/ap/financialnews/D9P1ERH80.htm |title=FDA approves Gilead-J&J HIV pill Complera |date=August 10, 2011 |work=[[Business Week]] }}</ref> It is available as a once-a-day single tablet. | |||
==Category== | ==Category== | ||
Revision as of 04:20, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.[1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011 (Eviplera),[2] for patients who have not previously been treated for HIV.[3] It is available as a once-a-day single tablet.
Category
Antiretroviral
US Brand Names
COMPLERA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
COMPLERA is a fixed-dose combination of the antiretroviral drugs emtricitabine, rilpivirine and tenofovir disoproxil fumarate.[4]
References
- ↑ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". Food and Drug Administration. August 10, 2011.
- ↑ "Eviplera; summary of the European public assessment report". European Medicines Agency. November 2011.
- ↑ "FDA approves Gilead-J&J HIV pill Complera". Business Week. August 10, 2011.
- ↑ "COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.]". Text " accessdate" ignored (help)